New Zealand standardised oral formulation batch sheet

Azathioprine suspension 50 mg/mL (50 mL)

Patient's name		**Storage condition**	**In a refrigerator**	**At room temperature**
NHI		Temperature	2-8°C	≤ 25°C
Date compounded		Shelf life	30 days	30 days
Batch number		Recommended storage	☑	May be stored at room temperature if this is more practical and temperatures greater than 25°C are avoided

Ingredients required and formula:

Ingredient	Supplier	Batch number	Expiry date	Standard formula	Quantity dispensed	Dispensed by	Checked by
Azathioprine 50 mg tablets				50 tablets			
Ora-Blend®	Perrigo			to 50 mL			
OR							
Ora-Plus®	Perrigo			25 mL			
Ora-Sweet®	Perrigo			25 mL			

Ora-Blend SF® or Ora-Sweet SF® (sugar free) can be substituted?	Yes
Calculations performed by	
Calculations checked by (pharmacist)	
Area cleared for processing by	

Instructions to compound suspension:

Note: **Cytotoxic** – Must use designated cytotoxic equipment and prepare in segregated area. Wear personal protective equipment.

1. **If Ora-Blend® is unavailable:** Pre-mix the Ora-Plus® and Ora-Sweet® to form the diluent.
2. Wet tablets with small amount of diluent (Ora-Blend® or prepared diluent) before crushing tablets in mortar to prevent exposure to medicine powder. Crush to form a smooth paste.
3. Gradually add the diluent (Ora-Blend® or prepared diluent) and transfer to the final measuring flask, rinsing mortar well. Mix well.
4. Make up to final volume and mix well.
5. Label and package product appropriately.

Labels	
Attach product label and auxiliary labels:	Label checked by

Azathioprine suspension 50 mg/mL (50 mL)

Final yield	_____ mL	Checked by	
Final appearance of product	Pale white suspension.		
Container	Amber plastic mission bottle.		
Compounded by	*Name:*	*Signature:*	*Date:*
Final check and product release	*Name:*	*Signature:*	*Date:*

Special instructions:

1. Cytotoxic.
2. Store in a refrigerator.
3. Shake well before use.

References:

1. Allen LV, Jr., Erickson MA, 3rd. *Am J Health Syst Pharm*, 1996; **53**(16): 1944-9.
2. Allen LV, Jr., Erickson MA, 3rd. *Secundum Artem*; **5**(4).

Prepared by	New Zealand Compounding Working Group		
Approved by	Medication Safety Expert Advisory Group of Health Quality and Safety Commission NZ		
Hosted by	Pharmaceutical Society of New Zealand Standard Formulations in the Practice Support section of the PSNZ website		
Version number	3.0	Version approval date	17/07/19
Document review due	01/08/21		